Indefinite Delivery Contract 75N93023D00014

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award Indefinite Delivery Contract to Latham Biopharm Group, Inc. to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million and a period of performance from January 2023 through September 2030, the contract enables ordering under five task areas: product development planning and evaluation, analytical assay development and product characterization, process development and related activities, CGMP manufacture and related activities, and regulatory activities and documentation. Services will support the assessment and advancement of therapeutic and diagnostic candidates through preclinical development and toward Investigational New Drug applications and other regulatory submissions to the U.S. Food and Drug Administration. The original solicitation sought responses from small businesses with relevant experience, staff, facilities, and safety plans to perform the work in compliance with applicable guidelines while advancing the National Institute of Allergy and Infectious Diseases' mission of understanding, treating, and preventing infectious, immunologic, and allergic diseases.

The contract was awarded as a single award to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases through five task areas: 1) product development planning and evaluation; 2) analytical assay development and product characterization; 3) process development and related activities; 4) CGMP manufacture and related activities; and 5) regulatory activities and documentation. The contract has a potential value of $30 million over a seven-year period of performance from January 2023 through September 2030, awarded by the National Institutes of Health National Institute of Allergy and Infectious Diseases to Latham Biopharm Group, Inc. The original solicitation sought responses from small businesses to perform the preclinical development work described across the five task areas in furtherance of the agency's mission to understand, treat, and prevent infectious diseases.